TCR2 Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

TCR2 Therapeutics

08/11/2022 12:46

* TCR2 Therapeutics Inc  TCRR.OQ  reported a quarterly
adjusted
loss of 79 cents​​ per share for the quarter ended in September.
The mean expectation of nine analysts for the quarter was for a
loss of 83 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * TCR2 Therapeutics Inc's reported EPS for the quarter was a
loss
of 79 cents​.
    * The mean earnings estimate of analysts had fallen by
about 8.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * TCR2 Therapeutics Inc shares had fallen by 23.3% this
quarter and lost 70.4% so far this year.
    * The company reported a quarterly loss of $30.59 million.
    * Wall Street's median 12-month price target for TCR2
Therapeutics
Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 12:46 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.83          -0.79          Beat
 Jun. 30 2022      -0.79          -0.82          Missed
 Mar. 31 2022      -0.74          -0.76          Missed
 Dec. 31 2021      -0.75          -0.72          Beat